<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="School of Medicine at Mount SinaiNew York, NYUnited States[], 2Kidney" exact="Disease" post="Branch, National Institute of Diabetes and Digestive and Kidney"/>
 <result pre="SinaiNew York, NYUnited States[], 2Kidney Disease Branch, National Institute of" exact="Diabetes" post="and Digestive and Kidney Diseases, National Institutes of HealthBethesda,"/>
 <result pre="2Kidney Disease Branch, National Institute of Diabetes and Digestive and" exact="Kidney" post="Diseases, National Institutes of HealthBethesda, MDUnited States[], 3Renal Unit,"/>
 <result pre="University Hospital of VeronaVeronaItaly[], 4Renal Division, Harvard Medical School, Massachusetts" exact="General" post="HospitalBoston, MAUnited States Edited by: Ying-Yong Zhao, Northwest University,"/>
 <result pre="does not comply with these terms. Abstract The new coronavirus" exact="disease" post="2019 (COVID-19) has become a world health emergency. The"/>
 <result pre="disease 2019 (COVID-19) has become a world health emergency. The" exact="disease" post="predominantly effects individuals between 30 and 79 years of"/>
 <result pre="cold, COVID-19 has also induced alveolar damage resulting in progressive" exact="respiratory" post="failure with fatalities noted in 6.4% of cases. Direct"/>
 <result pre="respiratory failure with fatalities noted in 6.4% of cases. Direct" exact="viral" post="injury, uncontrolled inflammation, activation of coagulation, and complement cascades"/>
 <result pre="with fatalities noted in 6.4% of cases. Direct viral injury," exact="uncontrolled" post="inflammation, activation of coagulation, and complement cascades are thought"/>
 <result pre="of coagulation, and complement cascades are thought to participate in" exact="disease" post="pathogenesis. Patients with COVID-19 have displayed kidney damage through"/>
 <result pre="to participate in disease pathogenesis. Patients with COVID-19 have displayed" exact="kidney damage" post="through acute kidney injury, mild proteinuria, hematuria, or slight"/>
 <result pre="disease pathogenesis. Patients with COVID-19 have displayed kidney damage through" exact="acute" post="kidney injury, mild proteinuria, hematuria, or slight elevation in"/>
 <result pre="pathogenesis. Patients with COVID-19 have displayed kidney damage through acute" exact="kidney injury," post="mild proteinuria, hematuria, or slight elevation in creatinine possibly"/>
 <result pre="COVID-19 on patients with pre-existing kidney impairment, including those with" exact="chronic" post="kidney disease, kidney transplant recipients, and individuals on hemodialysis"/>
 <result pre="on patients with pre-existing kidney impairment, including those with chronic" exact="kidney disease," post="kidney transplant recipients, and individuals on hemodialysis (HD) has"/>
 <result pre="against COVID-19 and are currently being tested in clinical trials." exact="acute" post="kidney injury AKI COVID-19 dialysis transplant fig-count: table-count: equation-count:"/>
 <result pre="COVID-19 and are currently being tested in clinical trials. acute" exact="kidney injury" post="AKI COVID-19 dialysis transplant fig-count: table-count: equation-count: ref-count: page-count:"/>
 <result pre="COVID-19 dialysis transplant fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first described in"/>
 <result pre="dialysis transplant fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), first described in humans"/>
 <result pre="transplant fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), first described in humans in"/>
 <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), first described in humans in December"/>
 <result pre="in the last 20 years. Previous outbreaks of the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002 and the Middle"/>
 <result pre="the last 20 years. Previous outbreaks of the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002 and the Middle East"/>
 <result pre="last 20 years. Previous outbreaks of the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002 and the Middle East respiratory"/>
 <result pre="respiratory syndrome coronavirus (SARS-CoV) in 2002 and the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012 have been toppled in"/>
 <result pre="syndrome coronavirus (SARS-CoV) in 2002 and the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012 have been toppled in case"/>
 <result pre="by the World Health (1). Presentation of symptoms for COVID-19" exact="infection" post="can be seen 2â€&quot;14 days after exposure. These symptoms"/>
 <result pre="and difficult breathing (4, 5). A severe complication of this" exact="disease" post="is progressive respiratory failure, and death may occur in"/>
 <result pre="(4, 5). A severe complication of this disease is progressive" exact="respiratory" post="failure, and death may occur in 6.4% of the"/>
 <result pre="emerging evidence indicates that kidney complications are frequent, and COVID-19" exact="disease" post="may have unique features in individuals on chronic dialysis"/>
 <result pre="and COVID-19 disease may have unique features in individuals on" exact="chronic" post="dialysis and kidney transplant recipients (8). SARS-CoV-2 and COVID-19"/>
 <result pre="virus jumped between host species from the bat, or an" exact="intermediate" post="animal, before spreading amongst the human population (4). The"/>
 <result pre="al. demonstrated that ACE2 is highly expressed in the alveolar" exact="epithelial" post="type II cells (AECII), suggesting that these cells could"/>
 <result pre="demonstrated that ACE2 is highly expressed in the alveolar epithelial" exact="type II" post="cells (AECII), suggesting that these cells could be the"/>
 <result pre="that the AECII cells have several genes related to the" exact="viral" post="process, replication, life cycle and assembly, therefore facilitating the"/>
 <result pre="viral process, replication, life cycle and assembly, therefore facilitating the" exact="viral" post="replication in the lung (10). Figure 1 SARS-CoV-2 entry"/>
 <result pre="the spike protein of SARS-CoV-2. After binding to ACE2, the" exact="viral" post="spike glycoprotein is primed by a host serine protease"/>
 <result pre="utilizing the cellular transcriptional machinery. ACE2, Angiotensin-Converting Enzyme 2; SARS-CoV-2," exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2; TMPRSS2, Transmembrane Serine Protease"/>
 <result pre="the cellular transcriptional machinery. ACE2, Angiotensin-Converting Enzyme 2; SARS-CoV-2, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2; TMPRSS2, Transmembrane Serine Protease 2."/>
 <result pre="cellular transcriptional machinery. ACE2, Angiotensin-Converting Enzyme 2; SARS-CoV-2, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2; TMPRSS2, Transmembrane Serine Protease 2. After"/>
 <result pre="transcriptional machinery. ACE2, Angiotensin-Converting Enzyme 2; SARS-CoV-2, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2; TMPRSS2, Transmembrane Serine Protease 2. After binding"/>
 <result pre="15): (1) an initial specific adaptive immune response and (2)" exact="uncontrolled" post="inflammation. The adaptive response is required during the early"/>
 <result pre="the early stages of incubation to prevent the progression of" exact="disease" post="and eliminate the virus. When the protective immune response"/>
 <result pre="propagates, inducing destruction of the affected tissues leading to severe" exact="disease" post="progression (15). An uncontrolled inflammatory response is also implicated"/>
 <result pre="the affected tissues leading to severe disease progression (15). An" exact="uncontrolled" post="inflammatory response is also implicated in COVID-19, as a"/>
 <result pre="is also implicated in COVID-19, as a mechanism responsible for" exact="acute" post="respiratory distress syndrome (ARDS). The release of a cytokine"/>
 <result pre="also implicated in COVID-19, as a mechanism responsible for acute" exact="respiratory" post="distress syndrome (ARDS). The release of a cytokine storm"/>
 <result pre="in COVID-19, as a mechanism responsible for acute respiratory distress" exact="syndrome" post="(ARDS). The release of a cytokine storm may promote"/>
 <result pre="This violent assault can be seen in patients with severe" exact="disease" post="who's plasma levels of IL-6, TNFÎ±, and IL-10 are"/>
 <result pre="are higher, and circulating CD4 and CD8 T cells are" exact="lower" post="than patients with mild COVID-19 or healthy controls (17)."/>
 <result pre="with exhaustion phenotype. Therefore, it is tempting to speculate that" exact="uncontrolled" post="inflammation, while promoting ARDS, impairs viral clearance by inducing"/>
 <result pre="tempting to speculate that uncontrolled inflammation, while promoting ARDS, impairs" exact="viral" post="clearance by inducing T cell exhaustion (18). Complement Activation"/>
 <result pre="is essential to respond rapidly to infection. During inflammation, both" exact="acute" post="and chronic, activation of the complement system promotes the"/>
 <result pre="of pathogens. Dysregulation of the complement system may lead to" exact="acute" post="lung disease after a highly pathogenic viruses infections (19)."/>
 <result pre="pathogens. Dysregulation of the complement system may lead to acute" exact="lung disease" post="after a highly pathogenic viruses infections (19). Complement activation"/>
 <result pre="Dysregulation of the complement system may lead to acute lung" exact="disease" post="after a highly pathogenic viruses infections (19). Complement activation"/>
 <result pre="lead to acute lung disease after a highly pathogenic viruses" exact="infections" post="(19). Complement activation through the lectin pathway has already"/>
 <result pre="to the implicated role of complement in the pathogenesis of" exact="acute" post="lung injury and ARDS, ongoing clinical trials are testing"/>
 <result pre="are testing the hypothesis that blocking the complement cascade ameliorates" exact="disease" post="severity in COVID-19 patients. Hypercoagulability and Thrombosis in COVID-19"/>
 <result pre="blocking the complement cascade ameliorates disease severity in COVID-19 patients." exact="Hypercoagulability" post="and Thrombosis in COVID-19 In general, altered hemostasis due"/>
 <result pre="complement cascade ameliorates disease severity in COVID-19 patients. Hypercoagulability and" exact="Thrombosis" post="in COVID-19 In general, altered hemostasis due to viral"/>
 <result pre="and Thrombosis in COVID-19 In general, altered hemostasis due to" exact="viral" post="infections often leads to vascular complications like thrombosis and"/>
 <result pre="Thrombosis in COVID-19 In general, altered hemostasis due to viral" exact="infections" post="often leads to vascular complications like thrombosis and or"/>
 <result pre="general, altered hemostasis due to viral infections often leads to" exact="vascular" post="complications like thrombosis and or hemorrhage. Vascular and endothelial"/>
 <result pre="due to viral infections often leads to vascular complications like" exact="thrombosis" post="and or hemorrhage. Vascular and endothelial changes by the"/>
 <result pre="often leads to vascular complications like thrombosis and or hemorrhage." exact="Vascular" post="and endothelial changes by the virus as well as"/>
 <result pre="as inherited host factors help define the clinical presentation. Some" exact="viral" post="contributions to the ischemic and thrombotic environment include procoagulant"/>
 <result pre="induces plaque rupture (22â€&quot;25). This can be seen with many" exact="respiratory" post="viruses like H1N1 influenza (26) and is of increasing"/>
 <result pre="COVID-19 patients show signs of increased coagulation activity, resulting in" exact="consumption" post="of coagulation factors and disseminated microvascular thrombosis. Hypoxia associated"/>
 <result pre="coagulation factors and disseminated microvascular thrombosis. Hypoxia associated with COVID-19" exact="pneumonia" post="increases blood viscosity both directly and through hypoxia-inducible transcription"/>
 <result pre="directly and through hypoxia-inducible transcription factor-dependent signaling pathway thereby promoting" exact="thrombosis" post="(27). Laboratory results indicate a prolongation of the prothrombin"/>
 <result pre="of the prothrombin time and international normalized ratio (PT/INR) and" exact="partial" post="thromboplastin time (PTT), elevation of D-dimer, decreased fibrinogen levels,"/>
 <result pre="elevation of D-dimer, decreased fibrinogen levels, thrombocytopenia, and schistocytes in" exact="peripheral" post="blood smears. In one study of 449 COVID-19 patients,"/>
 <result pre="one study of 449 COVID-19 patients, 71% of non-survivors had" exact="diffuse" post="intravascular coagulation (DIC) compared to 0.4% of survivors (27)."/>
 <result pre="&amp;lt;1 Î¼g/mL in a retrospective study of 191 COVID-19 patients." exact="Elevated" post="D-dimer at admission and markedly increasing D-dimer levels during"/>
 <result pre="D-dimer at admission and markedly increasing D-dimer levels during the" exact="disease" post="were associated with high mortality (27). Recently, anti-phospholipid antibodies"/>
 <result pre="high mortality (27). Recently, anti-phospholipid antibodies and infarcts in multiple" exact="vascular" post="territories have been reported in three COVID-19 patients with"/>
 <result pre="the thrombotic risk associated with prolonged bed resting (27). COVID-19" exact="Disease" post="Natural History SARS-CoV-2 rapidly spread throughout the world since"/>
 <result pre="date have not reported at least one case of the" exact="disease" post="within their borders. One infected patient may transmit the"/>
 <result pre="of the SARS-CoV-2 occurs through direct human-to-human contact and through" exact="respiratory" post="droplets in the air or on surfaces (31). The"/>
 <result pre="for over 3 h without a significant reduction in its" exact="infectious" post="titer and for up to 72 h on plastic"/>
 <result pre="Approximately 80% of patients infected by SARS-CoV-2 present with mild" exact="disease" post="and can recover spontaneously (34). The other 20% of"/>
 <result pre="spontaneously (34). The other 20% of patients present with severe" exact="disease" post="and 6% become critically ill (35). In these symptomatic"/>
 <result pre="severe disease and 6% become critically ill (35). In these" exact="symptomatic" post="patients, the main signs manifest as an upper respiratory"/>
 <result pre="In these symptomatic patients, the main signs manifest as an" exact="upper respiratory tract infection," post="cough, fever, and asthenia. Patients with severe disease will"/>
 <result pre="these symptomatic patients, the main signs manifest as an upper" exact="respiratory" post="tract infection, cough, fever, and asthenia. Patients with severe"/>
 <result pre="respiratory tract infection, cough, fever, and asthenia. Patients with severe" exact="disease" post="will present with pneumonia suspected by the presence of"/>
 <result pre="fever, and asthenia. Patients with severe disease will present with" exact="pneumonia" post="suspected by the presence of decreased oxygen saturation, lymphopenia"/>
 <result pre="with pneumonia suspected by the presence of decreased oxygen saturation," exact="lymphopenia" post="and increased inflammatory markers (CRP, D-dimer, ferritin) (4, 36)."/>
 <result pre="(CRP, D-dimer, ferritin) (4, 36). Chest CT scans usually show" exact="bilateral" post="involvement of the lungs, with consolidation in subsegmental areas"/>
 <result pre="involvement of the lungs, with consolidation in subsegmental areas (16)." exact="Viral" post="pneumonia can evolve into severe acute hypoxic respiratory failure"/>
 <result pre="of the lungs, with consolidation in subsegmental areas (16). Viral" exact="pneumonia" post="can evolve into severe acute hypoxic respiratory failure mediated"/>
 <result pre="in subsegmental areas (16). Viral pneumonia can evolve into severe" exact="acute" post="hypoxic respiratory failure mediated by increased pulmonary capillary permeability"/>
 <result pre="areas (16). Viral pneumonia can evolve into severe acute hypoxic" exact="respiratory" post="failure mediated by increased pulmonary capillary permeability and damage"/>
 <result pre="evolve into severe acute hypoxic respiratory failure mediated by increased" exact="pulmonary" post="capillary permeability and damage of the alveolar epithelial cell"/>
 <result pre="by increased pulmonary capillary permeability and damage of the alveolar" exact="epithelial" post="cell (35). The main risk factor for mortality due"/>
 <result pre="COVID-19 is advanced age. In patients with comorbidities, such as" exact="chronic" post="kidney disease, hypertension, chronic obstructive pulmonary disease, diabetes, tumor,"/>
 <result pre="is advanced age. In patients with comorbidities, such as chronic" exact="kidney disease," post="hypertension, chronic obstructive pulmonary disease, diabetes, tumor, and obesity,"/>
 <result pre="In patients with comorbidities, such as chronic kidney disease, hypertension," exact="chronic" post="obstructive pulmonary disease, diabetes, tumor, and obesity, advanced age"/>
 <result pre="with comorbidities, such as chronic kidney disease, hypertension, chronic obstructive" exact="pulmonary" post="disease, diabetes, tumor, and obesity, advanced age was the"/>
 <result pre="chronic kidney disease, hypertension, chronic obstructive pulmonary disease, diabetes, tumor," exact="and obesity," post="advanced age was the strongest predictor of a poor"/>
 <result pre="age was the strongest predictor of a poor outcome with" exact="infection" post="(33, 35, 37). Male sex has also been proposed"/>
 <result pre="studies (1), but this is not an universal finding (38)." exact="Kidney" post="Involvement During COVID-19 Li et al. (39) analyzed kidney"/>
 <result pre="that in 147 patients, 60% exhibited proteinuria and 48% exhibited" exact="hematuria" post="(not peer-reviewed) (39). D-dimer was elevated in 70% of"/>
 <result pre="patients, 55 patients presented with AKI as defined by the" exact="Kidney" post="Disease Improving Global Outcomes (KDIGO). These patients were significantly"/>
 <result pre="55 patients presented with AKI as defined by the Kidney" exact="Disease" post="Improving Global Outcomes (KDIGO). These patients were significantly older,"/>
 <result pre="significantly older, more likely male, and with other comorbidities, including" exact="chronic" post="renal insufficiency, hypertension, and cerebrovascular disease, and tended to"/>
 <result pre="older, more likely male, and with other comorbidities, including chronic" exact="renal insufficiency," post="hypertension, and cerebrovascular disease, and tended to have more"/>
 <result pre="and with other comorbidities, including chronic renal insufficiency, hypertension, and" exact="cerebrovascular disease," post="and tended to have more severe pneumonia (not peer-reviewed)"/>
 <result pre="hypertension, and cerebrovascular disease, and tended to have more severe" exact="pneumonia" post="(not peer-reviewed) (41). Of these patients, 14.3% presented with"/>
 <result pre="dialysis (44â€&quot;46). Careful fluid management to reduce the risk of" exact="pulmonary" post="edema in patients with severe ARDS from COVID-19 is"/>
 <result pre="ARDS from COVID-19 is the first goal, so in the" exact="absence of" post="hypotension and shock, a negative fluid balance of 0.5â€&quot;1.0"/>
 <result pre="on patients with COVID-19 (33), SARS-CoV-2 tends to affect the" exact="peripheral" post="and dorsal areas of the lungs. Prone positioning could"/>
 <result pre="to do CRRT for increased hemodynamic instability. Due to the" exact="hypercoagulability state" post="associated with COVID-19, systemic anticoagulation with unfractionated heparin or"/>
 <result pre="hemodynamic instability. Due to the hypercoagulability state associated with COVID-19," exact="systemic" post="anticoagulation with unfractionated heparin or regional citrate anticoagulation is"/>
 <result pre="function should be investigated further. The Mechanisms of SARS-CoV-2 Associated" exact="Kidney" post="Injury The exact mechanism of kidney involvement is unclear"/>
 <result pre="exact mechanism of kidney involvement is unclear and likely multifactorial." exact="Kidney" post="disease may be caused by SARS-CoV-2 binding to the"/>
 <result pre="mechanism of kidney involvement is unclear and likely multifactorial. Kidney" exact="disease" post="may be caused by SARS-CoV-2 binding to the ACE2"/>
 <result pre="(5). However, in another study, no urine tested positive for" exact="viral" post="RNA in 72 samples (55). Preliminary evidence in postmortem"/>
 <result pre="postmortem examinations of kidney tissue from six patients found severe" exact="acute" post="tubular necrosis and lymphocyte infiltration. Additionally, SARS-CoV-2 nucleocapsid protein"/>
 <result pre="autopsy of a kidney transplant patient who died of COVID-19," exact="viral" post="inclusion structures were found in the endothelial cells of"/>
 <result pre="were found in the endothelial cells of the kidney (57)." exact="Viral" post="infection could induce tubular damage through the deposition of"/>
 <result pre="found in the endothelial cells of the kidney (57). Viral" exact="infection" post="could induce tubular damage through the deposition of the"/>
 <result pre="tubules and infiltration of CD68+ macrophages in the tubule-interstitium (56)." exact="Diffuse" post="damage in proximal tubules with the loss of brush"/>
 <result pre="(58). In the peritubular and glomerular capillary of these autopsies," exact="diffuse" post="erythrocyte aggregation with endothelial damage, and obstruction without fibrin"/>
 <result pre="However, this finding could be non-specific as the presence of" exact="viral" post="proteins may not represent direct damage mediated by the"/>
 <result pre="glomerular cells in autopsies of three of six COVID-19 patients." exact="Kidney" post="biopsies in two Afro-American patients with high-risk APOL1 genotype"/>
 <result pre="in two Afro-American patients with high-risk APOL1 genotype and COVID-19" exact="infection" post="showed a collapsing focal segmental glomerulosclerosis (62, 63). However,"/>
 <result pre="with high-risk APOL1 genotype and COVID-19 infection showed a collapsing" exact="focal segmental glomerulosclerosis" post="(62, 63). However, SARS-CoV-2 RNA was not detected in"/>
 <result pre="APOL1 genotype and COVID-19 infection showed a collapsing focal segmental" exact="glomerulosclerosis" post="(62, 63). However, SARS-CoV-2 RNA was not detected in"/>
 <result pre="injury are sepsis, cytokine storm syndrome, shock/hemodynamic instability, rhabdomyolysis, and" exact="hypoxia" post="of kidney tissue (5, 48). Kidney biopsies would be"/>
 <result pre="shock/hemodynamic instability, rhabdomyolysis, and hypoxia of kidney tissue (5, 48)." exact="Kidney" post="biopsies would be helpful to better understand the histologic"/>
 <result pre="AKI. Unfortunately, this is very difficult to obtain given the" exact="respiratory" post="and hemodynamic instability of AKI patients and the use"/>
 <result pre="of exposure to personnel. COVID-19 in CKD Patients Patients with" exact="chronic" post="kidney disease (CKD) are known to have a higher"/>
 <result pre="exposure to personnel. COVID-19 in CKD Patients Patients with chronic" exact="kidney disease" post="(CKD) are known to have a higher risk of"/>
 <result pre="to personnel. COVID-19 in CKD Patients Patients with chronic kidney" exact="disease" post="(CKD) are known to have a higher risk of"/>
 <result pre="disease (CKD) are known to have a higher risk of" exact="upper respiratory tract infection" post="and pneumonia due to their persistent proinflammatory state with"/>
 <result pre="(CKD) are known to have a higher risk of upper" exact="respiratory" post="tract infection and pneumonia due to their persistent proinflammatory"/>
 <result pre="known to have a higher risk of upper respiratory tract" exact="infection" post="and pneumonia due to their persistent proinflammatory state with"/>
 <result pre="have a higher risk of upper respiratory tract infection and" exact="pneumonia" post="due to their persistent proinflammatory state with functional defects"/>
 <result pre="adaptive immunity (5). No study so far has found that" exact="chronic" post="kidney disease is statistically correlated with severe COVID-19. However,"/>
 <result pre="immunity (5). No study so far has found that chronic" exact="kidney disease" post="is statistically correlated with severe COVID-19. However, a significant"/>
 <result pre="(5). No study so far has found that chronic kidney" exact="disease" post="is statistically correlated with severe COVID-19. However, a significant"/>
 <result pre="when data of different studies were combined (64). COVID-19 in" exact="Kidney" post="Transplant Recipients Chronic immunosuppression is a well-known risk factor"/>
 <result pre="different studies were combined (64). COVID-19 in Kidney Transplant Recipients" exact="Chronic" post="immunosuppression is a well-known risk factor for viral and"/>
 <result pre="Transplant Recipients Chronic immunosuppression is a well-known risk factor for" exact="viral" post="and bacterial infections, but it is also crucial to"/>
 <result pre="Chronic immunosuppression is a well-known risk factor for viral and" exact="bacterial infections," post="but it is also crucial to prevent graft rejection"/>
 <result pre="also crucial to prevent graft rejection and to contrast the" exact="uncontrolled" post="antiviral inflammatory response. Therefore, the transplant community is puzzled"/>
 <result pre="in trying to understand the best therapeutic approach, in the" exact="absence of" post="any strong clinical data (8). So far, initial presentation"/>
 <result pre="did not report contact with infected individuals. Common symptoms at" exact="disease" post="onset have been fever, cough, asthenia, myalgias, and diarrhea"/>
 <result pre="at disease onset have been fever, cough, asthenia, myalgias, and" exact="diarrhea" post="(65). In a study of 36 transplant recipients, however,"/>
 <result pre="series, transplant patients show numerous radiopacity and patchy shadows on" exact="chest" post="radiographs often at presentation (67â€&quot;71). However, in one case"/>
 <result pre="case series of 15 kidney transplant patients, 33% had no" exact="acute" post="radiographic findings (72). Laboratory exams often showed lymphopenia with"/>
 <result pre="had no acute radiographic findings (72). Laboratory exams often showed" exact="lymphopenia" post="with lower CD3, CD4, and CD8 T cells especially"/>
 <result pre="acute radiographic findings (72). Laboratory exams often showed lymphopenia with" exact="lower" post="CD3, CD4, and CD8 T cells especially in those"/>
 <result pre="who had received antithymocyte globulin in the weeks before the" exact="infection" post="(66). Until more data is available, the rules to"/>
 <result pre="(66). Until more data is available, the rules to prevent" exact="viral infection" post="in the general population apply to transplant patients (hand"/>
 <result pre="Until more data is available, the rules to prevent viral" exact="infection" post="in the general population apply to transplant patients (hand"/>
 <result pre="patients could be present) (73). Transplant patients with potential COVID-19" exact="infection" post="should not access the transplant center due to risk"/>
 <result pre="should not access the transplant center due to risk of" exact="viral" post="spread. According to the European Renal Associationâ€&quot;European Dialysis and"/>
 <result pre="due to risk of viral spread. According to the European" exact="Renal" post="Associationâ€&quot;European Dialysis and Transplant Association (ERA-EDTA) guidelines (74), in"/>
 <result pre="(ERA-EDTA) guidelines (74), in patients with COVID-19 and without pneumonia," exact="complete" post="withdrawal of immunosuppressants -particularly calcineurin inhibitors (CNI)- is discouraged."/>
 <result pre="or mTOR-inhibitors should be individualized considering the severity of the" exact="disease" post="(74). The concurrent use of antivirals and anti-inflammatories should"/>
 <result pre="while converting those patients to hydrocortisone/solumedrol. This approach may improve" exact="viral" post="clearance but could lead to immune reconstitution and kidney's"/>
 <result pre="exacerbate inflammation, so this approach should be cautioned in the" exact="absence of" post="anti-inflammatory agents (see below). In some patients, tacrolimus reduction"/>
 <result pre="below). In some patients, tacrolimus reduction may be preferred over" exact="complete" post="withdrawal (67, 69) because of direct alleged CNI antiviral"/>
 <result pre="a case-by-case basis depending on the severity of pneumonia. Living" exact="Kidney" post="Donation During the COVID-19 Pandemic In countries with widespread"/>
 <result pre="deceased donor transplants should continue. However, donors at risk of" exact="infection" post="should not be accepted since RNAemia was reported in"/>
 <result pre="for non-life-saving organs should be considered in order to prevent" exact="infection" post="of the recipient during the post-transplant period. Even then,"/>
 <result pre="Even then, each kidney transplant should be considered case-by-case. COVID-19" exact="Infection" post="in Chronic Dialysis Patients Although it is known that"/>
 <result pre="each kidney transplant should be considered case-by-case. COVID-19 Infection in" exact="Chronic" post="Dialysis Patients Although it is known that diabetic nephropathy"/>
 <result pre="Infection in Chronic Dialysis Patients Although it is known that" exact="diabetic nephropathy" post="is an important comorbidity and AKI is one of"/>
 <result pre="in Chronic Dialysis Patients Although it is known that diabetic" exact="nephropathy" post="is an important comorbidity and AKI is one of"/>
 <result pre="for poor outcome during COVID-19 infection, the impact of the" exact="infection" post="on other kidney diseases, like end-stage renal disease, is"/>
 <result pre="during COVID-19 infection, the impact of the infection on other" exact="kidney diseases," post="like end-stage renal disease, is still unclear (8). Wang"/>
 <result pre="the impact of the infection on other kidney diseases, like" exact="end-stage renal disease," post="is still unclear (8). Wang et al. (78) described"/>
 <result pre="impact of the infection on other kidney diseases, like end-stage" exact="renal disease," post="is still unclear (8). Wang et al. (78) described"/>
 <result pre="related to pneumonia. The causes of death, in fact, were" exact="heart" post="failure, hyperkalemia, and cerebrovascular disease (not peer-reviewed) (79). In"/>
 <result pre="causes of death, in fact, were heart failure, hyperkalemia, and" exact="cerebrovascular disease" post="(not peer-reviewed) (79). In a report of five HD"/>
 <result pre="of death, in fact, were heart failure, hyperkalemia, and cerebrovascular" exact="disease" post="(not peer-reviewed) (79). In a report of five HD"/>
 <result pre="(not peer-reviewed) (79). In a report of five HD patients," exact="diarrhea" post="was the most common symptom, whereas fever, cough, and"/>
 <result pre="of 7,154 hemodialyzed patients, about 2% were confirmed having COVID-19" exact="infection" post="and only about 50% of them presented fever while"/>
 <result pre="CD8 T cells, NK cells, and proinflammatory cytokines are significantly" exact="lower" post="in COVID-19 HD patients, compared to non-HD COVID-19 individuals"/>
 <result pre="by SARS-CoV-2 are more likely to present mild symptoms with" exact="lower" post="risk of developing ARDS compared to COVID-19 patients not"/>
 <result pre="HD facilities has been recently released by the Centers for" exact="Disease" post="Control and Prevention (CDC) (84). Early recognition and isolation"/>
 <result pre="Prevention (CDC) (84). Early recognition and isolation of individuals with" exact="respiratory" post="infection, isolation of infected patients from other hemodialyzed patients,"/>
 <result pre="are sufficient, while during high-risk procedures, N95 respirators and other" exact="respiratory" post="protection devices are required. Chinese Society of Nephrology and"/>
 <result pre="(Table 1). Several broad-spectrum antiviral drugs, already approved for other" exact="viral" post="infections, are now being tested to treat COVID-19. Meanwhile,"/>
 <result pre="when anti-inflammatory therapy, like corticosteroids, could be harmful and induce" exact="viral" post="replication. However, once the disease is advanced and the"/>
 <result pre="could be harmful and induce viral replication. However, once the" exact="disease" post="is advanced and the hyper inflammation is the driver"/>
 <result pre="Steroids Broad anti-inflammatory effects, including inhibition of multiple cytokine expression" exact="Increased" post="death in a retrospective study on 548 patients (93)."/>
 <result pre="on 201 patients methylprednisolone was beneficial in those with severe" exact="disease" post="(94) IVIg Block FcR activation Only retrospective studies or"/>
 <result pre="effects Only case reports. Numerous ongoing trials Heparin Anticoagulant Improved" exact="hypoxia" post="in a case series (not peer-reviewed) (98) Drugs under"/>
 <result pre="proved benefit in triple therapy (101) Nitric Oxide Gas Inhibits" exact="viral" post="protein and RNA synthesis Ongoing trials Oseltamivir Viral neuraminidase"/>
 <result pre="Gas Inhibits viral protein and RNA synthesis Ongoing trials Oseltamivir" exact="Viral" post="neuraminidase inhibitor No effective outcomes in a retrospective study"/>
 <result pre="large retrospective studies (105, 106) Carrimycin Macrolide antibiotic Ongoing trials" exact="Vitamin C" post="Antioxidant properties Ongoing trials Ab: antibody; COX-2: cyclooxygenase-2; HCV:"/>
 <result pre="C Antioxidant properties Ongoing trials Ab: antibody; COX-2: cyclooxygenase-2; HCV:" exact="hepatitis C" post="virus; IL-6R: interleukin-6 (IL-6) receptor; NLRP3: NLR Family Pyrin"/>
 <result pre="RCT: randomized controlled trial; TMPRSS2: transmembrane serine protease 2; TNFÎ±:" exact="tumor" post="necrosis factor Î±; VEGF: vascular endothelial growth factor. Antivirals"/>
 <result pre="transmembrane serine protease 2; TNFÎ±: tumor necrosis factor Î±; VEGF:" exact="vascular" post="endothelial growth factor. Antivirals Lopinavir/Ritonavir Lopinavir/Ritonavir is a protease"/>
 <result pre="results, a Chinese clinical trial (ChiC-TR2000029308) in patients with SARS-CoV-2" exact="infection" post="showed that treatment with lopinavirâ€&quot;ritonavir added to standard supportive"/>
 <result pre="suggests potential efficacy of hydroxychloroquine, particularly combined with azithromycin, in" exact="viral" post="clearance. Hydroxychloroquine is often administered in conjunction with azithromycin,"/>
 <result pre="arrhythmias especially when combined with medications used to treat other" exact="chronic" post="conditions (e.g., kidney failure, hepatic disease). In a small"/>
 <result pre="combined with medications used to treat other chronic conditions (e.g.," exact="kidney failure," post="hepatic disease). In a small randomized study of 62"/>
 <result pre="improvement in the clinical recovery and in the resolution of" exact="pneumonia" post="compared to the control group (113). However, one observational"/>
 <result pre="is such sense of urgency, scrutiny and special attention to" exact="primary" post="data would be prudent. Favipiravir Favipiravir is a drug"/>
 <result pre="Favipiravir is a drug approved for treatment of severe influenza" exact="virus infection" post="in China. It is a new type of RNA-dependent"/>
 <result pre="is a drug approved for treatment of severe influenza virus" exact="infection" post="in China. It is a new type of RNA-dependent"/>
 <result pre="new type of RNA-dependent RNA polymerase (RdRp) inhibitor. It inhibits" exact="viral" post="polymerase activity because it can enter the cell and"/>
 <result pre="randomized, controlled, open-label multicenter trial, showed no significant difference in" exact="disease" post="recovery between 116 COVID-19 patients treated with favipiravir compared"/>
 <result pre="is an adenosine analog that can determine pre-mature termination of" exact="viral" post="RNA (108, 112). It is currently being tested for"/>
 <result pre="112). It is currently being tested for treatment of Ebola" exact="virus infection" post="and, in the future, might be useful to treat"/>
 <result pre="It is currently being tested for treatment of Ebola virus" exact="infection" post="and, in the future, might be useful to treat"/>
 <result pre="future, might be useful to treat several other RNA virus" exact="infections" post="(112, 115). Wang et al. (112) showed that viral"/>
 <result pre="virus infections (112, 115). Wang et al. (112) showed that" exact="viral" post="infections in a human cell line, which is sensitive"/>
 <result pre="infections (112, 115). Wang et al. (112) showed that viral" exact="infections" post="in a human cell line, which is sensitive to"/>
 <result pre="Goldman et al. (117) found that in 397 severe COVID-19" exact="pneumonia" post="patients without mechanical ventilation at baseline, there was no"/>
 <result pre="the neutralizing antibody titers significantly increased after plasma transfusion, the" exact="viral" post="load declined, and the clinical conditions improved (118). One"/>
 <result pre="convalescent plasma transfusion, with improvement of clinical symptoms, reduction of" exact="pulmonary" post="lesions, increase of lymphocytes count and titer of neutralizing"/>
 <result pre="cells (13). Camostat mesylate, already approved for some forms of" exact="cancer" post="and hepatitis, is being tested in ongoing clinical trial"/>
 <result pre="has been, at least in part, related to a sepsis-like" exact="syndrome" post="induced by high levels of circulating cytokines. Cytokine storm"/>
 <result pre="cytokines. Cytokine storm may be induced by a superimposed septic" exact="syndrome" post="or by the direct effect of the virus on"/>
 <result pre="not recommend the use of steroids because they could inhibit" exact="viral" post="clearance and prolongate viremia (48). Stockman et al. (120)"/>
 <result pre="cases steroids could be harmful presenting side effects like delayed" exact="viral" post="clearance, avascular necrosis, diabetes, and psychosis (33, 120). Therefore,"/>
 <result pre="could be harmful presenting side effects like delayed viral clearance," exact="avascular necrosis," post="diabetes, and psychosis (33, 120). Therefore, systemic use of"/>
 <result pre="side effects like delayed viral clearance, avascular necrosis, diabetes, and" exact="psychosis" post="(33, 120). Therefore, systemic use of glucocorticoids need to"/>
 <result pre="viral clearance, avascular necrosis, diabetes, and psychosis (33, 120). Therefore," exact="systemic" post="use of glucocorticoids need to be cautiously pursued (31)."/>
 <result pre="pursued (31). In a study of 548 patients with severe" exact="disease" post="treated with high-dose corticosteroids, patients had an increased death"/>
 <result pre="and ruxolitinib are potent anti-inflammatory drugs that are approved for" exact="rheumatoid arthritis" post="and myelofibrosis. Patients infected with SARS-CoV-2 often present increased"/>
 <result pre="ruxolitinib are potent anti-inflammatory drugs that are approved for rheumatoid" exact="arthritis" post="and myelofibrosis. Patients infected with SARS-CoV-2 often present increased"/>
 <result pre="the efficacy and safety of IVIg therapy in patients with" exact="pneumonia" post="caused by SARS-CoV-2. In a retrospective study of 58"/>
 <result pre="recovery and reduced 28-day mortality rate (95). Stem Cell Therapy" exact="Mesenchymal" post="stem cells (MSC) have immunomodulatory properties because they can"/>
 <result pre="the efficacy of the MSC treatment in patients with ARDS" exact="secondary" post="to Influenza A (H7N9) infection (124). Several ongoing clinical"/>
 <result pre="treatment in patients with ARDS secondary to Influenza A (H7N9)" exact="infection" post="(124). Several ongoing clinical trials are testing the mesenchymal"/>
 <result pre="therapy against SARS-CoV-2. IL-6-Inhibitors Tocilizumab, a drug used to treat" exact="rheumatoid arthritis," post="is a monoclonal antibody against the IL-6 receptor. Since"/>
 <result pre="(ChiCTR2000029765). The preliminary clinical results are encouraging (48). In an" exact="uncontrolled" post="study of 21 patients treated affected with severe COVID-19"/>
 <result pre="effects approved in China and Japan for the treatment of" exact="acute" post="pancreatitis and sepsis (123). There is an ongoing clinical"/>
 <result pre="approved in China and Japan for the treatment of acute" exact="pancreatitis" post="and sepsis (123). There is an ongoing clinical trial"/>
 <result pre="has been approved by the FDA for the treatment of" exact="rheumatoid arthritis" post="and neonatal-onset multisystem inflammatory disease. It is a recombinant"/>
 <result pre="been approved by the FDA for the treatment of rheumatoid" exact="arthritis" post="and neonatal-onset multisystem inflammatory disease. It is a recombinant"/>
 <result pre="by the FDA for the treatment of rheumatoid arthritis and" exact="neonatal-onset multisystem inflammatory disease." post="It is a recombinant human interleukin-1 receptor antagonist (IL-1Ra),"/>
 <result pre="tested in ongoing trials with COVID-19 patients to contrast the" exact="uncontrolled" post="inflammatory response. In one retrospective study of 29 patients"/>
 <result pre="of Anakinra in combination with standard treatment had a faster" exact="respiratory" post="improvement compared to 16 patients who received standard therapy"/>
 <result pre="can upregulate the expression and activity of the receptor in" exact="heart" post="and kidney tissue (127). These drugs are commonly prescribed"/>
 <result pre="tissue (127). These drugs are commonly prescribed for patients with" exact="diabetes" post="or cardiovascular disease who have higher risk of severe"/>
 <result pre="These drugs are commonly prescribed for patients with diabetes or" exact="cardiovascular disease" post="who have higher risk of severe COVID-19 disease which"/>
 <result pre="drugs are commonly prescribed for patients with diabetes or cardiovascular" exact="disease" post="who have higher risk of severe COVID-19 disease which"/>
 <result pre="or cardiovascular disease who have higher risk of severe COVID-19" exact="disease" post="which has raised concern for the use of these"/>
 <result pre="raised concern for the use of these drugs during the" exact="infection" post="(8). However, the increased expression of ACE2 could limit"/>
 <result pre="(8). However, the increased expression of ACE2 could limit the" exact="viral" post="spread because it is not accompanied by an increase"/>
 <result pre="has anti-proliferative and anti-fibrotic activity (8). Experimental animal models of" exact="acute" post="lung injury, including a model of SARS-CoV infection, showed"/>
 <result pre="ARBs reduce Ang II-mediated lung damage and therefore attenuate COVID-19" exact="infection" post="(127). In a retrospective study of 6,272 patients with"/>
 <result pre="but these drugs did not correlate with a more severe" exact="disease" post="after multivariable adjustment (105). The study by Reynolds et"/>
 <result pre="calcium-channel blockers, beta-blockers or thiazide diuretics and the risk of" exact="infection" post="or of having a severe disease in 5,894 patients."/>
 <result pre="and the risk of infection or of having a severe" exact="disease" post="in 5,894 patients. The European and American Cardiology Societies,"/>
 <result pre="having a severe disease in 5,894 patients. The European and" exact="American" post="Cardiology Societies, remarked that there is no evidence of"/>
 <result pre="SARS-CoV-2 effects on the kidney and in patient with underlying" exact="kidney disease" post="is not well-characterized. Preliminary data has indicated that previous"/>
 <result pre="effects on the kidney and in patient with underlying kidney" exact="disease" post="is not well-characterized. Preliminary data has indicated that previous"/>
 <result pre="disease is not well-characterized. Preliminary data has indicated that previous" exact="kidney disease" post="could represent a risk factor, especially in elderly patients,"/>
 <result pre="is not well-characterized. Preliminary data has indicated that previous kidney" exact="disease" post="could represent a risk factor, especially in elderly patients,"/>
 <result pre="risk factor, especially in elderly patients, for a more severe" exact="disease" post="course. SARS-CoV-2 infects the kidneys and may induce acute"/>
 <result pre="severe disease course. SARS-CoV-2 infects the kidneys and may induce" exact="acute" post="kidney injury. While there is no current specific therapy,"/>
 <result pre="disease course. SARS-CoV-2 infects the kidneys and may induce acute" exact="kidney injury." post="While there is no current specific therapy, many drugs"/>
 <result pre="in randomized trials. Further studies are necessary to better understand" exact="disease" post="pathology, acute kidney injury associated with infection, long-term renal"/>
 <result pre="trials. Further studies are necessary to better understand disease pathology," exact="acute" post="kidney injury associated with infection, long-term renal consequences, and"/>
 <result pre="Further studies are necessary to better understand disease pathology, acute" exact="kidney injury" post="associated with infection, long-term renal consequences, and potential therapies."/>
 <result pre="risk factor and the best therapeutic approaches to resolving COVID-19" exact="disease" post="outcomes. Author Contributions CB wrote manuscript the initial draft."/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="epidemic. Trop Med Int Health. (2020) 25:278â€&quot;80. 10.1111/tmi.1338332052514 5.ChengYLuoRWangKZhangMWangZDongLet al.." exact="Kidney" post="disease is associated with in-hospital death of patients with"/>
 <result pre="Trop Med Int Health. (2020) 25:278â€&quot;80. 10.1111/tmi.1338332052514 5.ChengYLuoRWangKZhangMWangZDongLet al.. Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19."/>
 <result pre="disease is associated with in-hospital death of patients with COVID-19." exact="Kidney" post="Int. (2020) 97:829â€&quot;38. 10.1016/j.kint.2020.03.00532247631 6.ZhouPYangXLWangXGHuBZhangLZhangWet al.. A pneumonia outbreak"/>
 <result pre="with COVID-19. Kidney Int. (2020) 97:829â€&quot;38. 10.1016/j.kint.2020.03.00532247631 6.ZhouPYangXLWangXGHuBZhangLZhangWet al.. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="579:270â€&quot;3. 10.1038/s41586-020-2012-732015507 7.VerityROkellLCDorigattiIWinskillPWhittakerCImaiNet al.. Estimates of the severity of coronavirus" exact="disease" post="2019: a model-based analysis. Lancet Infect Dis. (2020) 20:669â€&quot;77."/>
 <result pre="10.1016/S0140-6736(20)30183-531986264 17.WanSYiQFanSLvJZhangXGuoLet al.. Relationships among lymphocyte subsets, cytokines, and the" exact="pulmonary" post="inflammation index in coronavirus (COVID-19) infected patients. Br J"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19). Front Immunol. (2020) 11:827. 10.3389/fimmu.2020.0082732425950 19.CravediPHeegerPS. Complement"/>
 <result pre="ahead of print]. 21.MagroCMulveyJJBerlinDNuovoGSalvatoreSHarpJet al.. Complement associated microvascular injury and" exact="thrombosis" post="in the pathogenesis of severe COVID-19 infection: a report"/>
 <result pre="of five cases. Transl Res. (2020) 220:1â€&quot;13. 10.1016/j.trsl.2020.04.00732299776 22.SmeethLThomasSLHallAJHubbardRFarringtonPVallancePRisk of" exact="myocardial infarction" post="and stroke after acute infection or vaccination. N Engl"/>
 <result pre="Transl Res. (2020) 220:1â€&quot;13. 10.1016/j.trsl.2020.04.00732299776 22.SmeethLThomasSLHallAJHubbardRFarringtonPVallancePRisk of myocardial infarction and" exact="stroke" post="after acute infection or vaccination. N Engl J Med."/>
 <result pre="(2020) 220:1â€&quot;13. 10.1016/j.trsl.2020.04.00732299776 22.SmeethLThomasSLHallAJHubbardRFarringtonPVallancePRisk of myocardial infarction and stroke after" exact="acute" post="infection or vaccination. N Engl J Med. (2004) 351:2611â€&quot;8."/>
 <result pre="220:1â€&quot;13. 10.1016/j.trsl.2020.04.00732299776 22.SmeethLThomasSLHallAJHubbardRFarringtonPVallancePRisk of myocardial infarction and stroke after acute" exact="infection" post="or vaccination. N Engl J Med. (2004) 351:2611â€&quot;8. 10.1056/NEJMoa04174715602021"/>
 <result pre="or vaccination. N Engl J Med. (2004) 351:2611â€&quot;8. 10.1056/NEJMoa04174715602021 23.Corrales-MedinaVFMusherDMWellsGAChirinosJAChenLFineMJ." exact="Cardiac" post="complications in patients with community-acquired pneumonia: incidence, timing, risk"/>
 <result pre="short-term mortality. Circulation. (2012) 125:773â€&quot;81. 10.1161/CIRCULATIONAHA.111.04076622219349 24.DavidsonJAWarren-GashC. Cardiovascular complications of" exact="acute" post="respiratory infections: current research and future directions. Expert Rev"/>
 <result pre="mortality. Circulation. (2012) 125:773â€&quot;81. 10.1161/CIRCULATIONAHA.111.04076622219349 24.DavidsonJAWarren-GashC. Cardiovascular complications of acute" exact="respiratory" post="infections: current research and future directions. Expert Rev Anti"/>
 <result pre="10.1080/14787210.2019.168981731684779 25.ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="27.TangNBaiHChenXGongJLiDSunZAnticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094â€&quot;9."/>
 <result pre="J Med. (2020) 382:1677â€&quot;9. 10.1056/NEJMp200376232109012 30.HoehlSRabenauHBergerAKortenbuschMCinatlJBojkovaDet al.. Evidence of SARS-CoV-2" exact="infection" post="in returning travelers from Wuhan, China. N Engl J"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Mil Med Res. (2020) 7:4. 10.1186/s40779-020-0233-632029004 32.van"/>
 <result pre="(2020) 382:1564â€&quot;7. 10.1056/NEJMc200497332182409 33.PhuaJWengLLingLEgiMLimCMDivatiaJVet al.. Intensive care management of coronavirus" exact="disease" post="2019 (COVID-19): challenges and recommendations. Lancet Respir Med. (2020)"/>
 <result pre="10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].32205204 35.GuanWNiZHuYLiangWOuCHeJet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. (2020) 382:1708â€&quot;20."/>
 <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
 <result pre="al.. Clinical characteristics of fatal and recovered cases of coronavirus" exact="disease" post="2019 in Wuhan, China: a retrospective study. Chin Med"/>
 <result pre="retrospective study. Chin Med J. (2020) 133:1261â€&quot;7. 10.1097/CM9.000000000000082432209890 38.WangLLiXChenHYanSLiDLiYet al.Coronavirus" exact="disease" post="19 infection does not result in acute kidney injury:"/>
 <result pre="Chin Med J. (2020) 133:1261â€&quot;7. 10.1097/CM9.000000000000082432209890 38.WangLLiXChenHYanSLiDLiYet al.Coronavirus disease 19" exact="infection" post="does not result in acute kidney injury: an analysis"/>
 <result pre="10.1097/CM9.000000000000082432209890 38.WangLLiXChenHYanSLiDLiYet al.Coronavirus disease 19 infection does not result in" exact="acute" post="kidney injury: an analysis of 116 hospitalized patients from"/>
 <result pre="patients. medRxiv. (2020). 10.1101/2020.02.08.20021212. [Epub ahead of print]. 40.PeiGZhangZPengJLiuLZhangCYuCet al.." exact="Renal" post="involvement and early prognosis in patients with COVID-19 pneumonia."/>
 <result pre="pneumonia. J Am Soc Nephrol. (2020) 31:1157â€&quot;65. 10.1681/ASN.202003027632345702 41.XiaoGHuHWuFShaTHuangQLiHet al.Acute" exact="kidney injury" post="in patients hospitalized with COVID-19 in Wuhan, China: a"/>
 <result pre="study. medRxiv. (2020). 10.1101/2020.04.06.20055194. [Epub ahead of print]. 42.HirschJSNgJHRossDWSharmaPShahHHBarnettRLet al.." exact="Acute" post="kidney injury in patients hospitalized with COVID-19. Kidney Int."/>
 <result pre="medRxiv. (2020). 10.1101/2020.04.06.20055194. [Epub ahead of print]. 42.HirschJSNgJHRossDWSharmaPShahHHBarnettRLet al.. Acute" exact="kidney injury" post="in patients hospitalized with COVID-19. Kidney Int. (2020) 98:209â€&quot;18."/>
 <result pre="42.HirschJSNgJHRossDWSharmaPShahHHBarnettRLet al.. Acute kidney injury in patients hospitalized with COVID-19." exact="Kidney" post="Int. (2020) 98:209â€&quot;18. 10.1016/j.kint.2020.05.00632416116 43.DurvasulaRWellingtonTMcNamaraEWatnickS. COVID-19 and kidney failure"/>
 <result pre="with COVID-19. Kidney Int. (2020) 98:209â€&quot;18. 10.1016/j.kint.2020.05.00632416116 43.DurvasulaRWellingtonTMcNamaraEWatnickS. COVID-19 and" exact="kidney failure" post="in the acute care setting: our experience from seattle."/>
 <result pre="(2020) 98:209â€&quot;18. 10.1016/j.kint.2020.05.00632416116 43.DurvasulaRWellingtonTMcNamaraEWatnickS. COVID-19 and kidney failure in the" exact="acute" post="care setting: our experience from seattle. Am J Kidney"/>
 <result pre="the acute care setting: our experience from seattle. Am J" exact="Kidney" post="Dis. (2020) 76:4â€&quot;6. 10.1053/j.ajkd.2020.04.00132276031 44.EdreesFLiTVijayanA. Prolonged intermittent renal replacement"/>
 <result pre="(2020) 76:4â€&quot;6. 10.1053/j.ajkd.2020.04.00132276031 44.EdreesFLiTVijayanA. Prolonged intermittent renal replacement therapy. Adv" exact="Chronic" post="Kidney Dis. (2016) 23:195â€&quot;202. 10.1053/j.ackd.2016.03.00327113696 45.CullisBAbdelraheemMAbrahamsGBalbiACruzDNFrishbergYet al.. Peritoneal dialysis"/>
 <result pre="76:4â€&quot;6. 10.1053/j.ajkd.2020.04.00132276031 44.EdreesFLiTVijayanA. Prolonged intermittent renal replacement therapy. Adv Chronic" exact="Kidney" post="Dis. (2016) 23:195â€&quot;202. 10.1053/j.ackd.2016.03.00327113696 45.CullisBAbdelraheemMAbrahamsGBalbiACruzDNFrishbergYet al.. Peritoneal dialysis for"/>
 <result pre="Kidney Dis. (2016) 23:195â€&quot;202. 10.1053/j.ackd.2016.03.00327113696 45.CullisBAbdelraheemMAbrahamsGBalbiACruzDNFrishbergYet al.. Peritoneal dialysis for" exact="acute" post="kidney injury. Perit Dial Int J Int Soc Perit"/>
 <result pre="Dis. (2016) 23:195â€&quot;202. 10.1053/j.ackd.2016.03.00327113696 45.CullisBAbdelraheemMAbrahamsGBalbiACruzDNFrishbergYet al.. Peritoneal dialysis for acute" exact="kidney injury." post="Perit Dial Int J Int Soc Perit Dial. (2014)"/>
 <result pre="at: http://www.nephjc.com/news/covidaki (accessed April 09, 2020). 47.MatthayMAAldrichJMGottsJE. Treatment for severe" exact="acute" post="respiratory distress syndrome from COVID-19. Lancet Respir Med. (2020)"/>
 <result pre="http://www.nephjc.com/news/covidaki (accessed April 09, 2020). 47.MatthayMAAldrichJMGottsJE. Treatment for severe acute" exact="respiratory" post="distress syndrome from COVID-19. Lancet Respir Med. (2020) 8:433â€&quot;4."/>
 <result pre="April 09, 2020). 47.MatthayMAAldrichJMGottsJE. Treatment for severe acute respiratory distress" exact="syndrome" post="from COVID-19. Lancet Respir Med. (2020) 8:433â€&quot;4. 10.1016/S2213-2600(20)30127-232203709 48.NaickerSYangCWHwangSJLiuBCChenJHJhaV."/>
 <result pre="8:433â€&quot;4. 10.1016/S2213-2600(20)30127-232203709 48.NaickerSYangCWHwangSJLiuBCChenJHJhaV. The novel coronavirus 2019 epidemic and kidneys." exact="Kidney" post="Int. (2020) 97:824â€&quot;8. 10.1016/j.kint.2020.03.00132204907 49.RoncoCReisT. Kidney involvement in COVID-19"/>
 <result pre="2019 epidemic and kidneys. Kidney Int. (2020) 97:824â€&quot;8. 10.1016/j.kint.2020.03.00132204907 49.RoncoCReisT." exact="Kidney" post="involvement in COVID-19 and rationale for extracorporeal therapies. Nat"/>
 <result pre="kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy." exact="Kidney" post="Int Rep. (2020) 5:580â€&quot;5. 10.1016/j.ekir.2020.04.00132292866 52.LanJGeJYuJShanSZhouHFanSet al.. Structure of"/>
 <result pre="Multiomics evaluation of gastrointestinal and other clinical characteristics of severe" exact="acute" post="respiratory syndrome coronavirus 2 and coronavirus disease 2019. Gastroenterology."/>
 <result pre="evaluation of gastrointestinal and other clinical characteristics of severe acute" exact="respiratory" post="syndrome coronavirus 2 and coronavirus disease 2019. Gastroenterology. (2020)"/>
 <result pre="of gastrointestinal and other clinical characteristics of severe acute respiratory" exact="syndrome" post="coronavirus 2 and coronavirus disease 2019. Gastroenterology. (2020) 158:2298â€&quot;301.e7."/>
 <result pre="characteristics of severe acute respiratory syndrome coronavirus 2 and coronavirus" exact="disease" post="2019. Gastroenterology. (2020) 158:2298â€&quot;301.e7. S0016508520303991.32234303 55.WangWXuYGaoRLuRHanKWuGet al.. Detection of"/>
 <result pre="10.1001/jama.2020.378632159775 56.DiaoBWangCWangRFengZTanYWangHet al.Human kidney is a target for novel severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. (2020). 10.1101/2020.03.04.20031120."/>
 <result pre="56.DiaoBWangCWangRFengZTanYWangHet al.Human kidney is a target for novel severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. (2020). 10.1101/2020.03.04.20031120. [Epub"/>
 <result pre="al.Human kidney is a target for novel severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection. medRxiv. (2020). 10.1101/2020.03.04.20031120. [Epub ahead"/>
 <result pre="(2020). 10.1101/2020.03.04.20031120. [Epub ahead of print]. 57.VargaZFlammerAJSteigerPHabereckerMAndermattRZinkernagelASet al.. Endothelial cell" exact="infection" post="and endotheliitis in COVID-19. Lancet. (2020) 395:1417â€&quot;8. 10.1016/S0140-6736(20)30937-532325026 58.SuHYangMWanCYiLXTangFZhuHYet"/>
 <result pre="and endotheliitis in COVID-19. Lancet. (2020) 395:1417â€&quot;8. 10.1016/S0140-6736(20)30937-532325026 58.SuHYangMWanCYiLXTangFZhuHYet al.." exact="Renal" post="histopathological analysis of 26 postmortem findings of patients with"/>
 <result pre="of 26 postmortem findings of patients with COVID-19 in China." exact="Kidney" post="Int. (2020) 98:219â€&quot;27. 10.1016/j.kint.2020.04.00332327202 59.CalomeniESatoskarAAyoubIBrodskySRovinBHNadasdyT. Multivesicular bodies mimicking SARS-CoV-2"/>
 <result pre="10.1016/j.kint.2020.04.00332327202 59.CalomeniESatoskarAAyoubIBrodskySRovinBHNadasdyT. Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19." exact="Kidney" post="Int. (2020) 98:233â€&quot;4. 10.1016/j.kint.2020.05.00332437766 60.MillerSEBrealeyJK. Visualization of putative coronavirus"/>
 <result pre="(2020) 98:233â€&quot;4. 10.1016/j.kint.2020.05.00332437766 60.MillerSEBrealeyJK. Visualization of putative coronavirus in kidney." exact="Kidney" post="Int. (2020) 98:231â€&quot;2. 10.1016/j.kint.2020.05.00432437764 61.PuellesVGLÃ¼tgehetmannMLindenmeyerMTSperhakeJPWongMNAllweissLet al.. Multiorgan and renal"/>
 <result pre="ahead of print].32402155 62.LarsenCPBourneTDWilsonJDSaqqaOSharshirMACollapsing glomerulopathy in a patient with COVID-19." exact="Kidney" post="Int Rep. (2020) 5:935â€&quot;9. 10.1016/j.ekir.2020.04.002 63.KisslingSRotmanSGerberCHalfonMLamothFComteDet al.. Collapsing glomerulopathy"/>
 <result pre="5:935â€&quot;9. 10.1016/j.ekir.2020.04.002 63.KisslingSRotmanSGerberCHalfonMLamothFComteDet al.. Collapsing glomerulopathy in a COVID-19 patient." exact="Kidney" post="Int. (2020) 98:228â€&quot;31. 10.1016/j.kint.2020.04.00632471639 64.HenryBMLippiG. Chronic kidney disease is"/>
 <result pre="in a COVID-19 patient. Kidney Int. (2020) 98:228â€&quot;31. 10.1016/j.kint.2020.04.00632471639 64.HenryBMLippiG." exact="Chronic" post="kidney disease is associated with severe coronavirus disease 2019"/>
 <result pre="a COVID-19 patient. Kidney Int. (2020) 98:228â€&quot;31. 10.1016/j.kint.2020.04.00632471639 64.HenryBMLippiG. Chronic" exact="kidney disease" post="is associated with severe coronavirus disease 2019 (COVID-19) infection."/>
 <result pre="COVID-19 patient. Kidney Int. (2020) 98:228â€&quot;31. 10.1016/j.kint.2020.04.00632471639 64.HenryBMLippiG. Chronic kidney" exact="disease" post="is associated with severe coronavirus disease 2019 (COVID-19) infection."/>
 <result pre="10.1016/j.kint.2020.04.00632471639 64.HenryBMLippiG. Chronic kidney disease is associated with severe coronavirus" exact="disease" post="2019 (COVID-19) infection. Int Urol Nephrol. (2020) 52:1193â€&quot;4. 10.1007/s11255-020-02451-932222883"/>
 <result pre="transplantation. N Engl J Med. (2020) 382:2475â€&quot;7. 10.1056/NEJMc201111732329975 67.BanerjeeDPopoolaJShahSSterICQuanVPhanishM. COVID-19" exact="infection" post="in kidney transplant recipients. Kidney Int. (2020) 97:1076â€&quot;82. 10.1016/j.kint.2020.03.01832354637"/>
 <result pre="(2020) 382:2475â€&quot;7. 10.1056/NEJMc201111732329975 67.BanerjeeDPopoolaJShahSSterICQuanVPhanishM. COVID-19 infection in kidney transplant recipients." exact="Kidney" post="Int. (2020) 97:1076â€&quot;82. 10.1016/j.kint.2020.03.01832354637 68.ZhuLXuXMaKYangJGuanHChenSet al.. Successful recovery of"/>
 <result pre="Int. (2020) 97:1076â€&quot;82. 10.1016/j.kint.2020.03.01832354637 68.ZhuLXuXMaKYangJGuanHChenSet al.. Successful recovery of COVID-19" exact="pneumonia" post="in a renal transplant recipient with long-term immunosuppression. Am"/>
 <result pre="outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia." exact="Kidney" post="Int. (2020) 97:1083â€&quot;8. 10.1016/j.kint.2020.04.00232354634 72.collab: The Columbia University Kidney"/>
 <result pre="pneumonia. Kidney Int. (2020) 97:1083â€&quot;8. 10.1016/j.kint.2020.04.00232354634 72.collab: The Columbia University" exact="Kidney" post="Transplant Program. Early description of coronavirus 2019 disease in"/>
 <result pre="Columbia University Kidney Transplant Program. Early description of coronavirus 2019" exact="disease" post="in kidney transplant recipients in New York. J Am"/>
 <result pre="10.1681/ASN.202003037532317402 73.AslamSMehraMR. COVID-19: yet another coronavirus challenge in transplantation. J" exact="Heart" post="Lung Transplant. (2020) 39:408â€&quot;9. 10.1016/j.healun.2020.03.00732253113 74.MaggioreUAbramowiczDCrespoMMariatCMjoenGPeruzziLet al.. How should"/>
 <result pre="inhibit virus replication and apoptosis in cells infected with feline" exact="immunodeficiency" post="virus. Vet Res Commun. (1998) 22:553â€&quot;63. 10.1023/A:100619780488810066129 77.RussellBMossCGeorgeGSantaolallaACopeAPapaSet al.."/>
 <result pre="hemodialysis and COVID-19: saving lives with caution, care, and courage." exact="Kidney" post="Med. (2020) 2:365â€&quot;6. 10.1016/j.xkme.2020.03.00332292905 79.MaYDiaoBLvXZhuJLiangWLiuLet al.COVID-19 in hemodialysis (HD)"/>
 <result pre="in hemodialysis patients: a report of 5 cases. Am J" exact="Kidney" post="Dis. (2020) 76:141â€&quot;43. 10.1053/j.ajkd.2020.03.00932240718 81.XiongFTangHLiuLTuCTianJBLeiCTet al.. Clinical characteristics of"/>
 <result pre="and COVID-19. J Am Soc Nephrol. (2020) 31:1409â€&quot;15. 10.1681/ASN.202004047032467113 83.KwanBCH." exact="Severe" post="acute respiratory syndrome in dialysis patients. J Am Soc"/>
 <result pre="COVID-19. J Am Soc Nephrol. (2020) 31:1409â€&quot;15. 10.1681/ASN.202004047032467113 83.KwanBCH. Severe" exact="acute" post="respiratory syndrome in dialysis patients. J Am Soc Nephrol."/>
 <result pre="J Am Soc Nephrol. (2020) 31:1409â€&quot;15. 10.1681/ASN.202004047032467113 83.KwanBCH. Severe acute" exact="respiratory" post="syndrome in dialysis patients. J Am Soc Nephrol. (2004)"/>
 <result pre="Am Soc Nephrol. (2020) 31:1409â€&quot;15. 10.1681/ASN.202004047032467113 83.KwanBCH. Severe acute respiratory" exact="syndrome" post="in dialysis patients. J Am Soc Nephrol. (2004) 15:1883â€&quot;8."/>
 <result pre="10.1073/pnas.200416811732253318 93.LiXXuSYuMWangKTaoYZhouYet al.. Risk factors for severity and mortality in" exact="adult" post="COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. (2020)"/>
 <result pre="(2020) 146: 110â€&quot;8. 10.1016/j.jaci.2020.04.00632294485 94.WuCChenXCaiYXiaJZhouXXuSet al.. Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="146: 110â€&quot;8. 10.1016/j.jaci.2020.04.00632294485 94.WuCChenXCaiYXiaJZhouXXuSet al.. Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="10.1016/j.jaci.2020.04.00632294485 94.WuCChenXCaiYXiaJZhouXXuSet al.. Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020)"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China. JAMA Intern Med. (2020) 13:e200994. 10.1001/jamainternmed.2020.099432167524"/>
 <result pre="Effect of regular intravenous immunoglobulin therapy on prognosis of severe" exact="pneumonia" post="in patients with COVID-19. J Infect. (2020). 10.1016/j.jinf.2020.03.044. [Epub"/>
 <result pre="al.. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19," exact="acute" post="respiratory distress syndrome, and hyperinflammation: a retrospective cohort study."/>
 <result pre="Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute" exact="respiratory" post="distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet"/>
 <result pre="study. Lancet Rheumatol. (2020) 2:e325â€&quot;31. 10.1016/S2665-9913(20)30127-232501454 98.NegriEMPilotoBMorinagaLKJardimCVPLamySAEDFerreiraMAet al.Heparin therapy improving" exact="hypoxia" post="in COVID-19 patients - a case series. medRxiv. (2020)."/>
 <result pre="is not associated with improved outcomes in patients with coronavirus" exact="disease" post="2019: a retrospective study. Clin Microbiol Infect. (2020) 26:917â€&quot;21."/>
 <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, China. JAMA. (2020) 323:1061â€&quot;9. 10.1001/jama.2020.158532031570 103.CantiniFNiccoliLMatarreseDNicastriEStobbionePGolettiD. Baricitinib"/>
 <result pre="of print].32333918 104.GrittiGRaimondiFRipamontiDRivaILandiFAlborghettiLet al.Use of siltuximab in patients with COVID-19" exact="pneumonia" post="requiring ventilatory support. medRxiv. (2020). 10.1101/2020.04.01.20048561. [Epub ahead of"/>
 <result pre="in native and immunosuppressed states: a clinicalâ€&quot;therapeutic staging proposal. J" exact="Heart" post="Lung Transplant. (2020) 39:405â€&quot;7. 10.1016/j.healun.2020.03.01232362390 108.DongLHuSGaoJ. Discovering drugs to"/>
 <result pre="Transplant. (2020) 39:405â€&quot;7. 10.1016/j.healun.2020.03.01232362390 108.DongLHuSGaoJ. Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19). Drug Discov Ther. (2020) 14:58â€&quot;60. 10.5582/ddt.2020.0101232147628 109.de"/>
 <result pre="FDA-approved compound library identifies four small-molecule inhibitors of middle east" exact="respiratory" post="syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother."/>
 <result pre="compound library identifies four small-molecule inhibitors of middle east respiratory" exact="syndrome" post="coronavirus replication in cell culture. Antimicrob Agents Chemother. (2014)"/>
 <result pre="al.. Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
 <result pre="115.MulanguSDoddLEDaveyRTTshiani MbayaOProschanMMukadiDet al.. A randomized, controlled trial of ebola virus" exact="disease" post="therapeutics. N Engl J Med. (2019) 381:2293â€&quot;303. 10.1056/NEJMoa191099331774950 116.GreinJOhmagariNShinDDiazGAspergesECastagnaAet"/>
 <result pre="extracorporeal therapies in intensive care: si vis pacem para bellum." exact="Blood" post="Purif. (2020) 49:255â€&quot;8. 10.1159/00050703932172242 120.StockmanLJBellamyRGarnerP. SARS: systematic review of"/>
 <result pre="124.ChenJHuCChenLTangLZhuYXuXet al.. Clinical study of mesenchymal stem cell treatment for" exact="acute" post="respiratory distress syndrome induced by epidemic Influenza A (H7N9)"/>
 <result pre="al.. Clinical study of mesenchymal stem cell treatment for acute" exact="respiratory" post="distress syndrome induced by epidemic Influenza A (H7N9) infection:"/>
 <result pre="study of mesenchymal stem cell treatment for acute respiratory distress" exact="syndrome" post="induced by epidemic Influenza A (H7N9) infection: a hint"/>
</results>
